Literature DB >> 27545716

Preventing newborn deaths due to prematurity.

Kishwar Azad1, Jiji Mathews2.   

Abstract

Preterm births (PTBs), defined as births before 37 weeks of gestation account for the majority of deaths in the newborn period. Prediction and prevention of PTB is challenging. A history of preterm labour or second trimester losses and accurate measurement of cervical length help to identify women who would benefit from progesterone and cerclage. Fibronectin estimation in the cervicovaginal secretions of a symptomatic woman with an undilated cervix can predict PTB within 10 days of testing. Antibiotics should be given to women with preterm prelabour rupture of membranes but tocolysis has a limited role in the management of preterm labour. Antenatal corticosteroids to prevent complications in the neonate should be given only when gestational age assessment is accurate PTB is considered imminent, maternal infection and the preterm newborn can receive adequate care. Magnesium sulphate for fetal neuroprotection should be given when delivery is imminent. After birth, most babies respond to simple interventions essential newborn care, basic care for feeding support, infections and breathing difficulties. Newborns weighing 2000 g or less, benefit from KMC. Babies, who are clinically unstable or cannot be given KMC may be nursed in an incubator or under a radiant warmer. Treatment modalities include oxygen therapy, CPAP, surfactant and assisted ventilation.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  KMC; antenatal corticosteroids; cerclage; essential newborn care; preterm birth; surfactant

Mesh:

Substances:

Year:  2016        PMID: 27545716     DOI: 10.1016/j.bpobgyn.2016.06.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  1 in total

1.  Artificial womb technology and the frontiers of human reproduction: conceptual differences and potential implications.

Authors:  Elizabeth Chloe Romanis
Journal:  J Med Ethics       Date:  2018-08-10       Impact factor: 2.903

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.